A5084650044- Respiratory viral infections research
- Viral Infections and Immunology Research
- Viral gastroenteritis research and epidemiology
- Human-Automation Interaction and Safety
- Autonomous Vehicle Technology and Safety
- Safety Warnings and Signage
- Parvovirus B19 Infection Studies
- Traffic and Road Safety
- Global Maternal and Child Health
- Animal Virus Infections Studies
- Neonatal Respiratory Health Research
- Cytomegalovirus and herpesvirus research
- Hepatitis Viruses Studies and Epidemiology
- SARS-CoV-2 and COVID-19 Research
- Maternal and Perinatal Health Interventions
- Influenza Virus Research Studies
- Assisted Reproductive Technology and Twin Pregnancy
Pfizer (United States)
2024-2025
Pfizer (United Kingdom)
2025
Shaanxi Normal University
2020-2023
Abstract Background RSV is an important cause of lower respiratory tract illness (LRTI) in older adults. RSVpreF a bivalent stabilized prefusion F vaccine containing antigens against RSV-A and RSV-B. In this phase 3 trial ≥60-year-olds, demonstrated efficacy (VE) 88.9% 77.8% RSV-associated LRTI with ≥3 symptoms at the end seasons 1 2, respectively. Here we describe final safety results present immunogenicity data. Methods This study was conducted over 2 seasons. Participants were randomized...
Abstract Background Pfizer’s bivalent respiratory syncytial virus prefusion F subunit vaccine (RSVpreF [ABRYSVO™]) was approved in the United States for prevention of lower tract infections (LRTI) caused by RSV individuals ≥60 years. The objective this analysis is assessing durability RSVpreF vaccination on immunologic response over time.Figure 1.RSV A GMTs and GMFRs Time Interval After Vaccination with RSVpreF, Country- Evaluable Immunogenicity PopulationGMT= geometric mean titer; GMFR=...
Abstract Background In May 2023, the FDA approved RSVpreF [ABRYSVO™] for prevention of lower respiratory tract infection (LRTI) caused by RSV in adults ≥60 years age. Here we present vaccine efficacy (VE) data from pivotal phase 3 global RENOIR study (NCT05035212) an understanding VE persistence through 2 seasons and its impact on healthcare utilization (HCU).Figure 1RSVpreF against LRTI-RSV Methods Participants were randomized 1:1 to receive bivalent or placebo followed over two (Season 1...
Abstract Background The RSV Vaccine Efficacy Study in Older Adults Immunized Against Disease (RENOIR) is a phase 3, multicenter, randomized, double-blinded, placebo-controlled study that demonstrated vaccine efficacy (VE) of bivalent RSVpreF to prevent lower respiratory tract illness (LRTI) caused by adults ≥ 60 years age over two seasons (NCT05035212). Here we present an analysis the broader public health impact vaccine. and Public Health Impact Vaccination with 1-Dose – mITT Population...
Concomitant administration may improve vaccination rates. This analysis of a phase 1/2 randomized study included 1073 healthy ≥65-year-olds who previously received ≥3 mRNA COVID-19 vaccine doses. Participants concomitantly administered RSVpreF and bivalent BA.4/BA.5-adapted BNT162b2 (concomitant administration) with or without quadrivalent influenza (QIV), admixed combined + (combined vaccine) QIV, RSVpreF, BNT162b2, QIV. Immunogenicity objectives demonstrating the noninferiority...
Background/Objectives: Individuals with immunocompromising conditions are at high risk of developing severe respiratory syncytial virus (RSV) illness. This phase 3, single-arm study assessed the safety and immunogenicity bivalent RSV prefusion F protein−based (RSVpreF) 120-µg vaccine in immunocompromised renally impaired adults. Methods: Participants were stratified by age group (18−<60-year-olds; ≥60-year-olds) received two RSVpreF doses 1 month apart (i.e., Dose 2, respectively)....
Abstract Background Older individuals and adults with certain chronic or immunocompromising health conditions are at increased risk of severe respiratory syncytial virus (RSV) disease. Methods In this phase 3 randomized trial RSVpreF safety immunogenicity in 18–59-year-olds high RSV disease, participants were 2:1 to 1 (120 µg) placebo dose. Primary endpoints included reactogenicity events adverse (AEs) through 7 days month after vaccination, respectively, serious AEs (SAEs) newly diagnosed...
Gestational age at delivery is reportedly associated with cognitive and non-cognitive development in early childhood. Delivery an earlier full-term gestational has been increased rate of caesarean section (C-section) delivery; the high C-section China implies that medically unnecessary also high. This study investigated relationships childhood rural China.